Advanced Search

Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > Articles online first > The Journal of Cardiovascular Surgery 2016 Sep 20



A Journal on Cardiac, Vascular and Thoracic Surgery

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632

Frequency: Bi-Monthly

ISSN 0021-9509

Online ISSN 1827-191X


The Journal of Cardiovascular Surgery 2016 Sep 20

Drug-eluting stents in superficial femoral artery treatment : could they be the standard of care?

Marc BOSIERS 1, Koen DELOOSE 1, Joren CALLAERT 1, Patrick PEETERS 2, Michel BOSIERS 3

1 AZ Sint-Blasius Hospital, Dendermonde, Belgium; 2 Imelda Hospital, Bonheiden, Belgium; 3 St. Franziskus-Hospital, Münster, Germany

Endovascular techniques have improved markedly over the past several decades. Plain Old Balloon Angioplasty can only reach patencies around 40% after 1 year. Scaffolding stents have resulted in improved short-term results but encountered limitations for longer-term durability. With the introduction of drug-eluting technologies the process of intimal hyperplasia might be slowed, resulting in improved long-term patency results. At first, limus eluting technologies were not able to transfer the enthusiasm from the coronaries to the infrainguinal vascular bed. However, the newer generation paclitaxel eluting technologies perform significantly better in femoropopliteal arteries than their non-eluting or non-coated counterparts. The results of a prospective randomized trial comparing DES versus DCB is eagerly awaited. For the moment there seems, based on the meta- analysis, no difference between the two treatment modalities. Although, we need to keep in mind that DCB perform worse in long calcified lesions.

language: English


top of page